Antifungal Activity of Colistin against Mucorales Species In Vitro and in a Murine Model of Rhizopus oryzae Pulmonary Infection

ABSTRACT In immunosuppressed hosts, mucormycosis is a life-threatening infection with few treatment options. We studied the activity of colistin (polymyxin E) against Mucorales species in vitro and in a murine model of pulmonary Rhizopus oryzae infection. Colistin exhibited fungicidal activity in vitro against Mucorales spores and mycelia. At the colistin MIC, initial R. oryzae hyphal damage was followed by rapid regrowth; however, regrowth was prevented by combining colistin with a subinhibitory concentration of amphotericin B. Using electron microscopy and FM4-64 staining, we demonstrated that colistin disrupts R. oryzae cytoplasmic and vacuolar membranes, resulting in the leakage of intracellular contents. The prophylactic intranasal treatment of immunosuppressed mice with colistimethate significantly reduced the mortality rate and pulmonary fungal burden resulting from inhalational challenge with R. oryzae spores, whereas intraperitoneal colistimethate treatment had no effect. We conclude that colistin has modest in vitro and in vivo fungicidal activity against Mucorales spp. Further studies are warranted to assess the use of this drug in the prevention and treatment of mucormycosis.

[1]  G. Samonis,et al.  Increased virulence of Zygomycetes organisms following exposure to voriconazole: a study involving fly and murine models of zygomycosis. , 2009, The Journal of infectious diseases.

[2]  K. Tateda,et al.  Efficacy of colistin combination therapy in a mouse model of pneumonia caused by multidrug-resistant Pseudomonas aeruginosa. , 2009, The Journal of antimicrobial chemotherapy.

[3]  John Quale,et al.  Polymyxins Revisited , 2008, Clinical Microbiology Reviews.

[4]  E. Koratzanis,et al.  Colistin susceptibility testing by Etest and disk diffusion methods. , 2008, International journal of antimicrobial agents.

[5]  C. Gil-Lamaignere,et al.  Interaction of amphotericin B lipid formulations and triazoles with human polymorphonuclear leucocytes for antifungal activity against Zygomycetes , 2008, Mycoses.

[6]  L. B. Hovde,et al.  Colistin Methanesulfonate against Multidrug-Resistant Acinetobacter baumannii in an In Vitro Pharmacodynamic Model , 2007, Antimicrobial Agents and Chemotherapy.

[7]  D. Kontoyiannis,et al.  Invasive zygomycosis: update on pathogenesis, clinical manifestations, and management. , 2006, Infectious disease clinics of North America.

[8]  J. Li,et al.  Heteroresistance to Colistin in Multidrug-Resistant Acinetobacter baumannii , 2006, Antimicrobial Agents and Chemotherapy.

[9]  M. Falagas,et al.  The use of intravenous and aerosolized polymyxins for the treatment of infections in critically ill patients: a review of the recent literature. , 2006, Clinical medicine & research.

[10]  Russell E. Lewis,et al.  Lovastatin Has Significant Activity against Zygomycetes and Interacts Synergistically with Voriconazole , 2006, Antimicrobial Agents and Chemotherapy.

[11]  Russell E. Lewis,et al.  Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. , 2005, The Journal of infectious diseases.

[12]  Deborah L. Higgins,et al.  Telavancin, a Multifunctional Lipoglycopeptide, Disrupts both Cell Wall Synthesis and Cell Membrane Integrity in Methicillin-Resistant Staphylococcus aureus , 2005, Antimicrobial Agents and Chemotherapy.

[13]  D. Schmatz,et al.  The Antifungal Echinocandin Caspofungin Acetate Kills Growing Cells of Aspergillus fumigatus In Vitro , 2002, Antimicrobial Agents and Chemotherapy.

[14]  J. Peter,et al.  Testing Conditions for Determination of Minimum Fungicidal Concentrations of New and Established Antifungal Agents for Aspergillus spp.: NCCLS Collaborative Study , 2002, Journal of Clinical Microbiology.

[15]  M. Klepser,et al.  Comparison of Etest, chequerboard dilution and time-kill studies for the detection of synergy or antagonism between antifungal agents tested against Candida species. , 2002, The Journal of antimicrobial chemotherapy.

[16]  R. Stern,et al.  The Pharmacokinetics of Colistin in Patients with Cystic Fibrosis , 2001, Journal of clinical pharmacology.

[17]  R. Hancock,et al.  Peptide antibiotics , 1997, The Lancet.

[18]  S. Emr,et al.  A new vital stain for visualizing vacuolar membrane dynamics and endocytosis in yeast , 1995, The Journal of cell biology.

[19]  D. Schlessinger,et al.  Antifungal Properties of Polymyxin B and Its Potentiation of Tetracycline as an Antifungal Agent , 1972, Antimicrobial Agents and Chemotherapy.

[20]  C. Bracker,et al.  Protoplasmic Organization of Hyphal Tips Among Fungi: Vesicles and Spitzenkörper , 1970, Journal of bacteriology.

[21]  E. Friedman,et al.  The effects of renal impairment, peritoneal dialysis, and hemodialysis on serum sodium colistimethate levels. , 1968, Annals of internal medicine.

[22]  D. Kaye,et al.  SERUM CONCENTRATIONS OF COLISTIN IN PATIENTS WITH NORMAL AND IMPAIRED RENAL FUNCTION. , 1964, The New England journal of medicine.

[23]  Clinical,et al.  Reference method for broth dilution antifungal susceptibility testing of filamentous fungi : Approved standard , 2008 .

[24]  T. Walsh,et al.  Pulmonary zygomycosis. , 2008, Seminars in respiratory and critical care medicine.